A Dutch biotechnology company, ProQR Therapeutcis N.V., (NASDAQ:PRQR), Leiden, has announced the enrolment of a phase 2/3 study for the treatment of Leber Congenital Amaurosis… Read More »ProQR Therapeutics N.V. (NASDAQ: PRQR), expects to enrol 36 patients of LCA10 using a novel therapy for “Sepofarsen” (QR-110)
Genentech (a member of the Roche Group [SIX: RO, ROG; OTCQX: RHHBY]) have announced positive top-line results from two identically designed global Phase III studies,… Read More »Genentech (a subsidiary of Roche) has reported a key non-inferior end-point for faricimab for DME, gearing up for a head-to-head anti-VEGF market
A biotechnology company, Neurogene Inc., has raised $115 million in a second-round financing to be used to accelerate clinical trials. A range of treatments for… Read More »A biotechnology company founded by Neurogene Inc. (NY, USA) has raised $115M to focus on rare Batten disease.
Applied Genetic Technologies Corporation Inc. (Nasdaq: AGTC) has reported positive data from a Phase 1/2 clinical study for 28 X-linked retinitis pigmentosa (XLRP) patients. The company… Read More »Applied Genetic Technologies Corporation (NASDAQ: AGTC; Florida, USA) has reported positive data from a Phase 1/2 study for X-linked retinitis pigmentosa.
Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Vedere Bio, a venture based optogenetics company in Cambridge, Massachusetts. Vedere had developed… Read More »Novartis AG has acquired optogenetics company Vedere Bio for a value up to $280M.
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company has announced that the first patient has been dosed in the “AAVIATE” trial, a Phase II trial… Read More »Regenxbio Inc. has announced the first patient dosing of Phase II for RGX-314 gene therapy treatment for wet AMD
Novartis have reported two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials in wet AMD at the EURETINA 2020 virtual congress.… Read More »Novartis reported two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials at the EURETINA 2020 virtual congress
Gyroscope Therapeutics Ltd has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to GT005 for the treatment of geographic… Read More »Gyroscope Therapeutics Ltd, based in the UK, has received FDA Fast Track Designation for dry AMD treatment
GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, has announced the results from the final analysis of the REALITY natural history study, which reaffirms the poor… Read More »GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit.
Kubota Vision Inc. has announced that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) has awarded an orphan products clinical… Read More »Kubota Vision Inc., (Seattle, US) has received a $1.6M orphan products clinical trial support for Stargardt disease.